More than 400 international participants, including renowned scientists from research into umbilical cord blood and the resulting therapies as well as leading representatives of the pharmaceutical industry, made the recently concluded "Cord Blood Connect 2020" congress a complete success. Over a total of two days, the experts exchanged views virtually on new research approaches and advances in treatment methods due to the corona pandemic. The Leipzig umbilical cord blood bank Vita 34 sponsored the event, which gave concrete insight into the enormous potential of umbilical cord blood.
“The Cord Blood Connect Congress is the central specialist event when it comes to treatment methods with umbilical cord blood. It was impressive to see the advances that have already been made in the applications," says Dr. Wolfgang Knirsch. The CEO of Vita 34 explains: “The range of topics is very large. A particular focus was on the fight against or treatment of cancer and possible uses of stem cells from umbilical cord blood for the treatment of COVID-19. For our more than 230.000 customers from over 20 countries, the number of possible uses of the preparations stored with us could increase significantly in the future.”
PREPARATIONS REQUESTED FOR FURTHER RESEARCH AGAINST AUTISM
This year's Cord Blood Connect Congress clearly showed that treatment with stem cells from umbilical cord blood has long been established medicine. In 1988, umbilical cord blood was used as a therapy for the first time by Prof. Eliane Gluckmann. The physician herself spoke at the congress, as did representatives of renowned research institutions such as the MD Anderson Cancer Center (Houston, USA), Duke University (Durham, USA), the Fred Hutchinson Cancer Center (Seattle, USA), the University of Montreal or the University of Paris.
This shows that the need for therapies with stem cells, such as those found in umbilical cord blood, is growing. More than 80 different diseases are currently being treated with the help of stem cells as part of approved indications or clinical studies. At the same time, numerous research projects for future treatment approaches are running around the world.
Source: Press release from Vita 34 AG from October 12.10.2020th, XNUMX